Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

David J. Kuter, Waleed Ghanima, Umer Khan, Mengyao Li, Jenny Shan, Ahmed Daak, Nichola Cooper

Blood (2022) 140 (Supplement 1): 5559–5561.

https://doi.org/10.1182/blood-2022-162426

Published: 2022

Journal Articles

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Hagop Kantarjian, Susan O'Brien, Elias Jabbour, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, Jenny Shan, Mary Beth Rios, Farhad Ravandi, Stefan Faderl, Tapan Kadia, Gautam Borthakur, Xuelin Huang, Richard Champlin, Moshe Talpaz, Jorge Cortes

Blood (2012) 119 (9): 1981–1987.

https://doi.org/10.1182/blood-2011-08-358135

Published: 2012

Journal Articles

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Hun Lee, MD, Jorge E. Cortes, Susan O'Brien, MD, Elias Jabbour, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, MD, Jenny Shan, PhD, Mary Beth Rios, RN, Farhad Ravandi, MD, Stefan Faderl, MD, Tapan Kadia, Gautam Borthakur, Xuelin Huang, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 2750.

https://doi.org/10.1182/blood.V118.21.2750.2750

Published: 2011

Journal Articles

EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),

Aziz Nazha, Elias Jabbour, Jorge E. Cortes, Susan O'Brien, MD, Jenny Shan, PhD, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3769.

https://doi.org/10.1182/blood.V118.21.3769.3769

Published: 2011

Journal Articles

Dynamic Prognostic Model to Identify Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Mf) At the Highest Risk of Death and Transformation to Acute Myeloid Leukemia

Alfonso Quintás-Cardama, MD, Jenny Shan, PhD, Sherry Pierce, RN, BS, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 2821.

https://doi.org/10.1182/blood.V118.21.2821.2821

Published: 2011

Journal Articles

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

Elias Jabbour, Hagop Kantarjian, Susan O'Brien, Jenny Shan, Alfonso Quintas-Cardama, Stefan Faderl, Guillermo Garcia-Manero, Farhad Ravandi, Mary Beth Rios, Jorge Cortes

Blood (2011) 118 (17): 4541–4546.

https://doi.org/10.1182/blood-2011-04-348110

Published: 2011

Journal Articles

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

Elias Jabbour, Hagop Kantarjian, Susan O'Brien, Jenny Shan, Guillermo Garcia-Manero, William Wierda, Farhad Ravandi, Gautam Borthakur, Mary Beth Rios, Jorge Cortes

Blood (2011) 117 (6): 1822–1827.

https://doi.org/10.1182/blood-2010-07-293977

Published: 2011

Journal Articles

The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jorge Cortes, MD

Blood (2010) 116 (21): 3429.

https://doi.org/10.1182/blood.V116.21.3429.3429

Published: 2010

Journal Articles

Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

Alireza Eghtedar, MD, Stefan Faderl, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Tapan Kadia, MD, Sherry A. Pierce, RN, BS, Jenny Shan, PhD, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2010) 116 (21): 1085.

https://doi.org/10.1182/blood.V116.21.1085.1085

Published: 2010

Journal Articles

The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2 nd ) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS)

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD

Blood (2010) 116 (21): 2289.

https://doi.org/10.1182/blood.V116.21.2289.2289

Published: 2010

Journal Articles

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Elias Jabbour, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Jenny Shan, PhD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Farhad Ravandi, MD, Gautam Borthakur, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 509.

https://doi.org/10.1182/blood.V114.22.509.509

Published: 2009

Journal Articles

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Dushyant Verma, MD, FACP, Hagop M Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Amit Verma, MD, Elias Jabbour, MD, Srdan Verstovsek, MD, PhD, Tapan Kadia, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 505.

https://doi.org/10.1182/blood.V114.22.505.505

Published: 2009

Journal Articles

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

Jorge Cortes, Gautam Borthakur, Susan O'Brien, M.D., Dan Jones, Elias Jabbour, Farhad Ravandi, MD, Charles Koller, Brenda Walker, Jenny Shan, Hagop Kantarjian

Blood (2009) 114 (22): 338.

https://doi.org/10.1182/blood.V114.22.338.338

Published: 2009

Journal Articles

Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

Jorge Cortes, Susan O'Brien, Dan Jones, Elias Jabbour, Marina Konopleva, Alessandra Ferrajoli, Tapan Kadia, Gautam Borthakur, Denise Stigliano, Jenny Shan, Hagop Kantarjian

Blood (2009) 114 (22): 341.

https://doi.org/10.1182/blood.V114.22.341.341

Published: 2009

Journal Articles

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Jenny Shan, Susan O'Brien, Neeli Reddy, William G. Wierda, Stefan Faderl, Guillermo Garcia-Manero, Srdan Verstovsek, Mary Beth Rios, Jorge Cortes

Blood (2009) 113 (10): 2154–2160.

https://doi.org/10.1182/blood-2008-04-154344

Published: 2009

Journal Articles

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

Farhad Ravandi, MBBS, Jean-Pierre Issa, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Sherry Pierce, BSN, Jenny Shan, PhD, Srdan Verstovsek, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Hagop Kantarjian, MD

Blood (2008) 112 (11): 2955.

https://doi.org/10.1182/blood.V112.11.2955.2955

Published: 2008

Journal Articles

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (PTS) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Susan O’Brien, M.D., Gautam Borthakur, Srdan Verstovsek, William Wierda, Jenny Shan, Jorge Cortes, MD

Blood (2008) 112 (11): 2110.

https://doi.org/10.1182/blood.V112.11.2110.2110

Published: 2008

Journal Articles

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

Constantine S. Tam, Hagop Kantarjian, Guillermo Garcia-Manero, Gautam Borthakur, Susan O'Brien, Farhad Ravandi, Jenny Shan, Jorge Cortes

Blood (2008) 112 (3): 516–518.

https://doi.org/10.1182/blood-2008-02-141580

Published: 2008

Journal Articles

Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, MD, Hagop Kantarjian, MD, Jenny Shan, Susan O’Brien, MD, William Wierda, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Steven Kornblau, MD, Brenda K. Walker, RN, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2007) 110 (11): 1942.

https://doi.org/10.1182/blood.V110.11.1942.1942

Published: 2007

Journal Articles

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Deborah Thomas, M.D., Charles Koller, M.D., Jenny Shan, Jorge Cortes, M.D.

Blood (2007) 110 (11): 1955.

https://doi.org/10.1182/blood.V110.11.1955.1955

Published: 2007

NARROW

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),

Dynamic Prognostic Model to Identify Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Mf) At the Highest Risk of Death and Transformation to Acute Myeloid Leukemia

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).

Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2 nd ) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS)

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (PTS) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs).

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only